Medical is solving this problem.

We’ve developed the P-Scope: the world’s first FDA-cleared, disposable, and portable laparoscope for abdominal cavity examinations under local anesthesia. It delivers direct visualization at the point of care, dramatically accelerating diagnosis while reducing cost and clinical risk.

Key Advantages

No general anesthesia or CO₂ insufflation required. Single-use, eliminating cross-contamination and reprocessing. Compact, portable, and ready for use in any setting. Reusable processor + disposable scope model for efficiency.

Clinical Need

Existing imaging modalities (CT, USG, MRI) are often inconclusive. In critical cases—sepsis, peritoneal metastases, NEC, abdominal trauma—delays can be fatal. P-Scope offers immediate, minimally invasive insight without needing to transfer the patient.

Market Opportunity $40B global endoscopy market $4B+ segment in single-specialty diagnostic scopes Target: Critical care, trauma, pediatric, surgical units, and rural/emerging markets

Traction

FDA 510(k) clearance granted (K241502) Patents granted in AU & India; pending in the US, EU, Canada, Japan Strong early interest from clinicians and hospital systems Accepted into MassChallenge and Health Wildcatters Strategic manufacturing relationships established (BESDATA, OJOS Medical)

Business Model

Reusable image processor (capital) + Disposable laparoscope (razor/blade model) $200 cost vs. $2000 ASP = strong gross margins Focused on early B2B sales in the U.S. with global expansion pipeline

Team

Dr. Adarsh Patil, MD – Founder & CEO; surgeon with 15+ years in laparoscopic procedures Hrishikesh Gadagkar – Co-Founder & CTO; 30+ years in MedTech Backed by experienced advisors including FDA veterans, Stanford faculty, and commercialization experts Funding & Use of Proceeds Raising $5M Seed Round Goals: U.S. sales growth, clinical validation, market entry (EU, Canada), regulatory expansion Build out sales team, complete U.S. hospital onboarding, launch focused clinical pilots

Exit Strategy

OUI Medical is a high-potential acquisition target for:

Strategic buyers in the endoscopy/laparoscopy space (e.g., Medtronic, Stryker, Karl Storz, Olympus) Diagnostics and surgical platform companies seeking point-of-care tools Potential exit within 3–5 years via acquisition or strategic M&A Comparable MedTech exits in this space range from 5–15x revenue multiples Our unique positioning—disruptive product, strong IP, regulatory clearance, and high-margin model—makes OUI Medical a compelling acquisition as large players look to expand in point-of-care diagnostics.

OUI Medical is redefining how, where, and when abdominal diagnostics happen. Let’s bring life-saving insights to the bedside—globally.